Amgen, USB Pharma and Astellas funded the study, and Dr. McClung and other study authors report financial relationships with Amgen and other drug companies.
ad goes here:advert-1
SCROLL TO CONTINUE
- McClung MR, Brown JP, Diez-Perez A, et al. Effects of 24 months of treatment with romosozumab followed by 12 months of denosumab or placebo in postmenopausal women with low bone mineral density: A randomized, double-blind, phase 2, parallel group study. Journal of Bone Mineral Research. 2018 Apr 25. [Epub ahead of print]